NCT07227311 2026-06-02A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)GlaxoSmithKlinePhase 2 Recruiting200 enrolled